DGHMC
CPIX icon

Dalton, Greiner, Hartman, Maher & Co’s Cumberland Pharmaceuticals CPIX Stock Holding History

Dalton, Greiner, Hartman, Maher & Co’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-89,100
Closed -$528K – 162
2019
Q3 		$528K Buy
+89,100
New +$496K 0.04% 168

Other funds holding CPIX

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dalton, Greiner, Hartman, Maher & Co's CPIX Position: Q4 2019 in Review

Dalton, Greiner, Hartman, Maher & Co sold out of Cumberland Pharmaceuticals (CPIX) in Q4 2019, closing a stake of 89,100 shares — an estimated $528K sold.

Dalton, Greiner, Hartman, Maher & Co first reported a position in CPIX in Q3 2019 and held it in 1 quarter. The position peaked at $528K in Q3 2019. 27 funds tracked by Wall St. Rank hold CPIX as of Q4 2019.

  • Dalton, Greiner, Hartman, Maher & Co reported no remaining Cumberland Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Dalton, Greiner, Hartman, Maher & Co sold 89,100 Cumberland Pharmaceuticals shares in Q4 2019, an estimated $528K.
  • Dalton, Greiner, Hartman, Maher & Co first reported a position in Cumberland Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Dalton, Greiner, Hartman, Maher & Co's Cumberland Pharmaceuticals position peaked at $528K in Q3 2019.
  • 27 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q4 2019.

Based on Dalton, Greiner, Hartman, Maher & Co's 13F filing for Q4 2019, filed 15 Jan 2020.